The Lack of Antitumor Effects of o,p′DDA Excludes Its Role as an Active Metabolite of Mitotane for Adrenocortical Carcinoma Treatment-Reference-Cited by-同舟云学术

The Lack of Antitumor Effects of o,p′DDA Excludes Its Role as an Active Metabolite of Mitotane for Adrenocortical Carcinoma Treatment

Published:2014-07-16 Issue:5 Volume:5 Page:312-323
ISSN:1868-8497
Container-title:Hormones and Cancer
language:en
Short-container-title:HORM CANC

Author:

Hescot Ségolène,Paci Angelo,Seck Atmane,Slama Abdelhamid,Viengchareun Say,Trabado Séverine,Brailly-Tabard Sylvie,Al Ghuzlan Abir,Young Jacques,Baudin Eric,Lombès Marc

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Endocrine and Autonomic Systems,Endocrinology,Oncology,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s12672-014-0189-7.pdf

Reference35 articles.

1. Schteingart DE, Doherty GM, Gauger PG et al (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12:667–680. doi:10.1677/erc.1.01029

2. Berruti A, Baudin E, Gelderblom H et al (2012) Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol ESMO 23(Suppl 7):vii131–vii138. doi:10.1093/annonc/mds231

3. Baudin E, Leboulleux S, Al Ghuzlan A et al (2011) Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011? Horm Cancer 2:363–371. doi:10.1007/s12672-011-0094-2

4. Fassnacht M, Terzolo M, Allolio B et al (2012) Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366:2189–2197. doi:10.1056/NEJMoa1200966

5. Berruti A, Fassnacht M, Baudin E et al (2010) Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol Off J Am Soc Clin Oncol 28:e401–e402. doi:10.1200/JCO.2009.27.5958, author reply e403

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic value of total, free and lipoprotein fraction-bound plasma mitotane levels in advanced adrenocortical carcinoma: a prospective study of the ENDOCAN-COMETE-Cancer network;Journal of Endocrinological Investigation;2024-08-22

2. Albumin/Mitotane Interaction Affects Drug Activity in Adrenocortical Carcinoma Cells: Smoke and Mirrors on Mitotane Effect with Possible Implications for Patients’ Management;International Journal of Molecular Sciences;2023-11-24

3. Effects of o,p’-DDE, a Mitotane Metabolite, in an Adrenocortical Carcinoma Cell Line;Pharmaceuticals;2022-11-29

4. Mitotane treatment in adrenocortical carcinoma: mechanisms of action and predictive markers of response to therapy;Minerva Endocrinology;2021-12

5. Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies;Cancers;2021-10-20